<DOC>
	<DOC>NCT01420549</DOC>
	<brief_summary>The purpose of this study is to determine the non-inferiority between two different FDC, measuring LDL-Cholesterol levels, in high risk patients by NCEP-ATP III, with primary hypercholesterolemia or mixed dyslipidemia.</brief_summary>
	<brief_title>Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia</brief_title>
	<detailed_description>The propose of this study is to evaluate the efficacy of the combination Rosuvastatin + Ezetimibe noninferiority compared with simvastatin + ezetimibe combination - Vytorin ® - in control of LDL cholesterol compared to baseline stipulated in high-risk patients by NCEP-ATP III, patients with primary hypercholesterolemia or mixed dyslipidemia.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients of both sexes, aged between 18 and 70 years, remaining the feasibility of a legal guardian in accordance with need, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol; Confirmed diagnosis of primary hypercholesterolemia; Confirmed diagnosis of mixed dyslipidemia; Liver transaminases ≤ 2 x upper limit of normal with no active liver disease; Creatinine kinase (CK) less or equal the upper limit of normality; Patients should not have clinically significant comorbidities, which may interfere in the evaluation of study; Patients who is willing to maintain a cholesterollowering diet throughout the study; Patients need to agree in discontinue the previous medication for hypercholesterolemia treatment and switch to the study medication. Patients with primary hypercholesterolemia who have LDLC &gt; 160 mg/dl and &lt; 220 mg/dl; and triglyceride (TG) concentration &lt; 350 mg/dl Heart failure class III or IV (NYHA); Blood dyscrasia; Unstable angina pectoris; Myocardial infarction in the last 3 months; Planning for CABG, peripheral or carotid percutaneous intervention for the next 90 days; Renal insufficiency (estimated GFR &lt; 30 ml/min/m2); Liver transaminases &gt; 2 x upper limit of normal; Asian patients or kinship asian; History of alcoholism or drug abuse; Patients with comorbidities that hinder the interpretation of results or contraindicate the lipidlowering therapy [uncompensated hypothyroidism (TSH &gt; 8 mUI/mL); uncompensated diabetes (HbA1c &gt; 8%); active hepatic disease; antiretroviral therapy, neoplasm (except for adequately treated squamous cell skin cancer within the past 5 years), concomitant immunosuppressive therapy (transplanted and rheumatic disease). Noncompensated hypertension (BP ≥ 160/100 mm Hg); Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study; Woman in pregnancy or lactation period; Hypersensibility to ezetimibe or rosuvastatin, or any component of these medications; Participation in last one year of clinical protocols, unless it can be direct benefit to patient; Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the subject or interfere with the endpoints of study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>